采用动脉内卡铂诱导治疗，随后进行手术和/或放疗的晚期头颈癌的根治性和器官保留治疗：单中心五年结果

Curative and organ-preserving treatment with intra-arterial carboplatin induction followed by surgery and/or radiotherapy for advanced head and neck cancer: single-center five-year results.

作者信息

Bertino Giulia, Benazzo Marco, Gatti Patrizia, Bernardo Gianni, Corbella Franco, Tinelli Carmine, Zappoli Federico, Mira Eugenio

机构信息

Department of Otolaryngology, University of Pavia--IRCCS Policlinico S Matteo, Pavia, Italy.

出版信息

BMC Cancer. 2007 Apr 11;7:62. doi: 10.1186/1471-2407-7-62.

BACKGROUND

This study evaluated the feasibility, toxicity, response rate and survival of neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and neck cancer.

METHODS

Forty-six patients with primary head and neck squamous cell carcinoma received 3 cycles of intra-arterial carboplatin (300 to 350 mg/m2 per cycle every 2 weeks), followed by radiotherapy or surgery plus radiotherapy.

RESULTS

No complications or severe toxicity occurred. Sixteen patients (35%) were complete responders, 20 (43%) partial responders while 10 (22%) did not respond to treatment. After completion of the multimodality treatment, 38/46 patients (83%) were complete responders. After a 5-year follow-up period, 18/46 patients (39%) are alive and disease-free, 3 (6,5%) have died of a second primary tumor and 25 (54.5%) have died of the disease.

CONCLUSION

Intra-arterial carboplatin induction chemotherapy is a safe, well-tolerated technique that discriminates between responders and non-responders and so may have prognostic significance in planning further integrated treatments aimed to organ preservation for advanced head and neck carcinomas.

背景

本研究评估了高剂量卡铂新辅助超选择性动脉内灌注治疗晚期头颈癌的可行性、毒性、缓解率和生存率。

方法

46例原发性头颈鳞状细胞癌患者接受了3个周期的动脉内卡铂治疗（每2周1个周期，剂量为300至350mg/m²），随后接受放疗或手术加放疗。

结果

未发生并发症或严重毒性反应。16例患者（35%）为完全缓解者，20例（43%）为部分缓解者，10例（22%）对治疗无反应。多模式治疗完成后，46例患者中有38例（83%）为完全缓解者。经过5年的随访期，46例患者中有18例（39%）存活且无疾病，3例（6.5%）死于第二原发性肿瘤，25例（54.5%）死于该疾病。